Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003274 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00003274 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 48 participants.
The verdict
NCT00003274, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known what preparation of vaccine therapy is most effective for treating melanoma. PURPOSE: Randomized phase II trial to study the effectiveness of tyrosinase/gp100 peptide vaccine in treating patients who have stage II melanoma that can be removed by surgery.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
- BIOLOGICAL tyrosinase peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 1998-03 |
| Est. Completion | 2002-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003274
The ClinicalTrials.gov registry entry for NCT00003274 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which sargramostim is the first listed.
NCT00003274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003274 about?
NCT00003274 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known what preparation of vaccine therapy is most effective for treating melanoma. PURPOSE: Randomized phase II trial to study the effectiveness of tyrosinase/gp100 peptide vaccine in treating patients...
What is the current status of trial NCT00003274?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 1998-03. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00003274?
The interventions under investigation include: sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003274?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.